# Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

> **NCT05806814** · PHASE1 · RECRUITING · sponsor: **University of Oklahoma** · enrollment: 13 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer (mCRPC)

## Interventions

- **BIOLOGICAL:** Sipuleucel-T

## Key facts

- **NCT ID:** NCT05806814
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-12
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806814, "Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05806814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*